These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14717936)

  • 1. High dose chemotherapy in light chain or light and heavy chain deposition disease.
    Royer B; Arnulf B; Martinez F; Roy L; Flageul B; Etienne I; Ronco P; Brouet JC; Fermand JP
    Kidney Int; 2004 Feb; 65(2):642-8. PubMed ID: 14717936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resolution of mesangial light chain deposits 3 years after high-dose melphalan with autologous peripheral blood stem cell transplantation.
    Harada K; Akai Y; Sakan H; Yamaguchi Y; Nakatani K; Iwano M; Saito Y
    Clin Nephrol; 2010 Nov; 74(5):384-8. PubMed ID: 20979947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
    Child JA; Morgan GJ; Davies FE; Owen RG; Bell SE; Hawkins K; Brown J; Drayson MT; Selby PJ;
    N Engl J Med; 2003 May; 348(19):1875-83. PubMed ID: 12736280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
    Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
    Hassoun H; Flombaum C; D'Agati VD; Rafferty BT; Cohen A; Klimek VM; Boruchov A; Kewalramani T; Reich L; Nimer SD; Comenzo RL
    Bone Marrow Transplant; 2008 Sep; 42(6):405-12. PubMed ID: 18574442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency.
    Ballester OF; Tummala R; Janssen WE; Fields KK; Hiemenz JW; Goldstein SC; Perkins JB; Sullivan DM; Rosen R; Sackstein R; Zorsky P; Saez R; Elfenbein GJ
    Bone Marrow Transplant; 1997 Oct; 20(8):653-6. PubMed ID: 9383228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.
    Huijgens PC; Dekker-Van Roessel HM; Jonkhoff AR; Admiraal GC; Zweegman S; Schuurhuis GJ; Ossenkoppele GJ
    Bone Marrow Transplant; 2001 May; 27(9):925-31. PubMed ID: 11436102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma.
    Weaver CH; Zhen B; Schwartzberg LS; Leff R; Magee M; Geier L; Deaton K; Lewkow L; Buckner CD
    Bone Marrow Transplant; 1998 Aug; 22(3):245-51. PubMed ID: 9720737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.
    Cohen C; Royer B; Javaugue V; Szalat R; El Karoui K; Caulier A; Knebelmann B; Jaccard A; Chevret S; Touchard G; Fermand JP; Arnulf B; Bridoux F
    Kidney Int; 2015 Nov; 88(5):1135-43. PubMed ID: 26176826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
    Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
    Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients.
    Palumbo A; Triolo S; Baldini L; Callea V; Capaldi A; De Stefano V; Grasso M; Liberati M; Lotesoriere C; Marcenò R; Marmont F; Musto P; Petrucci MT; Spriano M; Pileri A; Boccadoro M
    Haematologica; 2000 May; 85(5):508-13. PubMed ID: 10800168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.
    Safadi S; Saad A; Quint PS; Sethi S; Leung N; Kurtin P; Nasr SH
    Nephrol Dial Transplant; 2015 Jul; 30(7):1151-5. PubMed ID: 25796445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.
    Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P
    Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin light chain amyloidosis and the kidney.
    Gertz MA; Lacy MQ; Dispenzieri A
    Kidney Int; 2002 Jan; 61(1):1-9. PubMed ID: 11786079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
    Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
    Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
    Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Light chain nephropathy: histological and clinical aspects in 15 cases.
    Confalonieri R; Barbiano di Belgiojoso G; Banfi G; Ferrario F; Bertani T; Pozzi C; Casanova S; Lupo A; De Ferrari G; Minetti L
    Nephrol Dial Transplant; 1988; 3(2):150-6. PubMed ID: 3140081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.